Literature DB >> 11198603

Renal dysfunction but not cystic change is ameliorated by neonatal epidermal growth factor in bpk mice.

K Nakanishi1, V H Gattone, W E Sweeney, E D Avner.   

Abstract

BALB/c mice homozygous for the bpk gene exhibit a form of autosomal recessive (AR) polycystic kidney disease (PKD) with massive collecting duct cysts, common bile duct dilation and chaotic intrahepatic bile ducts/portal triads. The combined renal and biliary pathology mimics much of the pathology seen in human ARPKD. Murine models of ARPKD generally have a reduced renal expression of epidermal growth factor (EGF) and an increased expression of EGF receptors (EGF-R). However, the role that EGF and EGF-R play in the progression of PKD has been unclear. Evidence from various model systems/ages of treatment produces conflicting results. Treating neonatal C57BL/6J-cpk mice with EGF ameliorates the renal pathology and dysfunction while treating 2- and 3-week-old bpk mice with an EGF-receptor tyrosine kinase inhibitor also ameliorates ARPKD. Therefore, to determine whether neonatal EGF treatment would accelerate or inhibit the progression of the PKD in bpk mice, we administered exogenous EGF (1 microgram/g body weight subcutaneously) daily from postnatal days 3-9 (a critical period for tubule maturation). Neonatal EGF treatment but not sham treatment retarded the development of azotemia and common bile duct dilation and the chaotic hepatic triad changes in cystic mice. However, EGF treatment neither reduced the severity of the renal cystic pathology nor reduced the degree of cystic enlargement of the kidneys. Cystic mice treated past 9 days of age died prior to their scheduled termination at 21 days of age. The role of EGF in the progression of polycystic kidney disease in bpk mice is relatively complicated, with neonatal treatment being associated with some amelioration of the renal dysfunction and extrarenal pathology without an effect on the renal pathology. Continuation of treatment beyond 9 days increased morbidity. Therefore, in discussing the role of EGF or EGF receptor in mediating the pathophysiology of PKD, the stage of development may be an important consideration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11198603     DOI: 10.1007/s004670000495

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

Review 1.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 2.  Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease.

Authors:  Carsten Bergmann; Valeska Frank; Fabian Küpper; Dirk Kamitz; Jens Hanten; Peter Berges; Silke Mager; Markus Moser; Jutta Kirfel; Reinhard Büttner; Jan Senderek; Klaus Zerres
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

3.  Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease.

Authors:  Raghad Nemo; Noel Murcia; Katherine Macrae Dell
Journal:  Pediatr Res       Date:  2005-03-17       Impact factor: 3.756

Review 4.  Novel targets for the treatment of autosomal dominant polycystic kidney disease.

Authors:  Franck A Belibi; Charles L Edelstein
Journal:  Expert Opin Investig Drugs       Date:  2010-03       Impact factor: 6.206

5.  Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease.

Authors:  Yasunori Sato; Kenichi Harada; Kazuo Kizawa; Takahiro Sanzen; Shinichi Furubo; Mitsue Yasoshima; Satoru Ozaki; Masahiko Ishibashi; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

Review 6.  The epidermal growth factor receptor pathway in chronic kidney diseases.

Authors:  Laura R Harskamp; Ron T Gansevoort; Harry van Goor; Esther Meijer
Journal:  Nat Rev Nephrol       Date:  2016-07-04       Impact factor: 28.314

7.  The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.

Authors:  Abeda Jamadar; Sreenath M Suma; Sijo Mathew; Timothy A Fields; Darren P Wallace; James P Calvet; Reena Rao
Journal:  Cell Death Dis       Date:  2021-10-14       Impact factor: 8.469

Review 8.  Role of epidermal growth factor receptor in acute and chronic kidney injury.

Authors:  Jinhua Tang; Na Liu; Shougang Zhuang
Journal:  Kidney Int       Date:  2013-01-16       Impact factor: 10.612

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.